User login
Experimental MLN9708 is the first oral proteasome inhibitor, and it has shown itself to be highly active in a phase I/II clinical trial that enrolled 65 patients with newly diagnosed multiple myeloma.
Investigators reported that 92% responded to an all-oral regimen combining MLN9708 with lenalidomide (Revlimid) and dexamethsone. This included 55% with at least a very good partial response and 23% in complete response. A phase III trial is planned
Patrice Wendling interviewed Dr. Shaji K. Kumar on findings he presented at the annual meeting of the American Society of Hematology.
Experimental MLN9708 is the first oral proteasome inhibitor, and it has shown itself to be highly active in a phase I/II clinical trial that enrolled 65 patients with newly diagnosed multiple myeloma.
Investigators reported that 92% responded to an all-oral regimen combining MLN9708 with lenalidomide (Revlimid) and dexamethsone. This included 55% with at least a very good partial response and 23% in complete response. A phase III trial is planned
Patrice Wendling interviewed Dr. Shaji K. Kumar on findings he presented at the annual meeting of the American Society of Hematology.
Experimental MLN9708 is the first oral proteasome inhibitor, and it has shown itself to be highly active in a phase I/II clinical trial that enrolled 65 patients with newly diagnosed multiple myeloma.
Investigators reported that 92% responded to an all-oral regimen combining MLN9708 with lenalidomide (Revlimid) and dexamethsone. This included 55% with at least a very good partial response and 23% in complete response. A phase III trial is planned
Patrice Wendling interviewed Dr. Shaji K. Kumar on findings he presented at the annual meeting of the American Society of Hematology.
